Overview
Understanding Halozyme Therapeutics integration
Who this is for: Wholesalers, distributors, pharmacies, hospitals and suppliers that trade with Halozyme Therapeutics, and their purchasing, contract and finance teams.
Scope: This guide describes typical practice for this kind of trading relationship; Halozyme Therapeutics's own program details are confirmed during onboarding.
Halozyme Therapeutics, based in San Diego, licenses drug delivery technology used to make subcutaneous formulations and also markets products with partners. ECOM's directory lists Halozyme Therapeutics under pharmaceutical manufacturing.
A technology licensor works mostly through licensing and royalty relationships, so supplier-side orders and invoices relate to its own purchasing and partnered product supply. A pharmaceutical manufacturer typically sells through wholesalers and specialty distributors rather than directly to every pharmacy, so the main documents are orders and shipment notices from the wholesaler side, plus resale (867), inventory and chargeback (844) reporting. Direct accounts, such as hospitals or large chains, add invoices and remittance. DSCSA serialization data travels with product as a supply program requirement. The document set below is typical practice for this type of company; confirm the documents, X12 version, delivery method and testing steps with Halozyme Therapeutics for your own program.
ECOM helps confirm your trading program, map the required documents, configure connectivity, and complete testing against the applicable specifications. It then monitors every file after go-live and handles partner changes, as software, as a managed service or both.